Cidara Therapeutics, Inc. (CDTX)
NASDAQ: CDTX · IEX Real-Time Price · USD
11.93
-0.11 (-0.91%)
At close: Jul 2, 2024, 4:00 PM
11.70
-0.23 (-1.93%)
After-hours: Jul 2, 2024, 4:02 PM EDT
Cidara Therapeutics Stock Forecast
Stock Price Forecast
The 3 analysts with 12-month price forecasts for Cidara Therapeutics stock have an average target of 61.67, with a low estimate of 25 and a high estimate of 120. The average target predicts an increase of 416.93% from the current stock price of 11.93.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 16, 2024.
Analyst Ratings
The average analyst rating for CDTX stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
Rating | Jan '24 | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 |
---|---|---|---|---|---|---|
Strong Buy | 2 | 2 | 2 | 3 | 3 | 3 |
Buy | 1 | 1 | 1 | 1 | 1 | 1 |
Hold | 0 | 0 | 0 | 0 | 0 | 0 |
Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Total | 3 | 3 | 3 | 4 | 4 | 4 |
Latest Forecasts
Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
---|---|---|---|---|---|---|---|
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Jun 20, 2024 |
Needham | Needham | Strong Buy Reiterates $25 | Strong Buy | Reiterates | $25 | +109.56% | May 16, 2024 |
WBB Securities | WBB Securities | Strong Buy Maintains $40 | Strong Buy | Maintains | $40 | +235.29% | Apr 25, 2024 |
Needham | Needham | Strong Buy Maintains $3 → $25 | Strong Buy | Maintains | $3 → $25 | +109.56% | Apr 25, 2024 |
Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates n/a | Buy | Reiterates | n/a | n/a | Apr 25, 2024 |
Financial Forecast
Revenue This Year
26.27M
from 63.91M
Decreased by -58.90%
Revenue Next Year
10.91M
from 26.27M
Decreased by -58.45%
EPS This Year
-17.84
from -5.20
EPS Next Year
-8.84
from -17.84
Revenue Forecast
Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | 41.3M | 22.5M | 28.6M | 256.8M | 193.0M |
Avg | 26.3M | 10.9M | 13.9M | 93.9M | 107.1M |
Low | 12.0M | n/a | n/a | n/a | 39.0M |
Revenue Growth
Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -35.4% | -14.4% | 161.7% | 1,751.5% | 105.6% |
Avg | -58.9% | -58.4% | 27.1% | 576.7% | 14.1% |
Low | -81.3% | - | - | - | -58.5% |
EPS Forecast
EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | -18.36 | -9.10 | -8.09 | 42.34 | 23.10 |
Avg | -17.84 | -8.84 | -7.85 | 19.92 | 10.83 |
Low | -17.14 | -8.50 | -7.55 | -1.23 | -0.74 |
EPS Growth
EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
---|---|---|---|---|---|
High | - | - | - | - | 16.0% |
Avg | - | - | - | - | -45.6% |
Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.